Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer
S Al-Samsam, J Bartoš, V Šámal… - Reports of Practical …, 2024 - journals.viamedica.pl
Background: The aim was to assess therapeutic outcomes and tolerance in patients wit hm
etastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor …
etastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor …